Teneobio will utilize Selexis’ proprietary SUREtechnology Platform™ to develop research cell banks (RCBs) for three additional preclinical candidates for the potential treatments of B-cell malignan...
Industry Experts to Provide Strategic Guidance as the Companies Advance Technologies Used in the Discovery, Analytics and Manufacturing of Difficult-to-Express Biologics